Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL11199481 | 1.00 | CA5A (0.86) | — | |
| Sulfuric Acid SCHEMBL19625 | 1.00 | CA5A (0.86) | — | |
| Sulfuric Acid SCHEMBL11181920 | 1.00 | CA5A (0.86) | — | |
| Sulfuric Acid SCHEMBL17478063 | 1.00 | CA5A (0.86) | — | |
| Sulfuric Acid SCHEMBL8546516 | 1.00 | CA5A (0.86) | — | |
| Sulfuric Acid SCHEMBL8620979 | 1.00 | CA5A (0.86) | — | |
| Sulfuric Acid SCHEMBL6368575 | 1.00 | CA5A (0.86) | — | |
| Sulfuric Acid SCHEMBL296213 | 1.00 | CA5A (0.86) | — | |
| Sulfuric Acid SCHEMBL5718234 | 1.00 | CA5A (0.86) | — | |
| Sulfuric Acid SCHEMBL2456365 | 1.00 | CA5A (0.86) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | claimed |
| EP-4460301-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2024-11-13 | — | — | EP | claimed |
| WO-2023131576-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2023-07-13 | — | — | WO | claimed |
| EP-4209213-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2023-07-12 | — | — | EP | claimed |
| EP-1453843-B1 | POWDER TRACE ELEMENT, METHOD AND DEVICE FOR MAKING SAME | PANCOSMA S A (CH) | 2013-05-08 | — | — | EP | claimed |
| US-7553367-B2 | Method of making a diL-lysine monosulfate trihydrate crystal | AJINOMOTO CO., INC. (JP) | 2009-06-30 | — | — | US | claimed |
| US-20090023775-A1 | 1-[2-(4-BENZYL-4-HYDROXY-PIPERIDIN-1 -YL )-ETHYL]-3-(2-METHYL-QUINOLIN- 4-YL)- UREA AS CRYSTALLINE SULFATE SALT | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-01-22 | — | — | US | claimed |
| EP-1802604-A1 | 1-[2-(4-BENZYL-4-HYDROXY-PIPERIDIN-1-YL)-ETHYL]-3-(2-METHYL-QUINOLIN-4-YL)-UREA AS CRYSTALLINE SULFATE SALT | Actelion Pharmaceuticals Ltd. (CH) | 2007-07-04 | — | — | EP | claimed |
| WO-2006040728-A1 | 1-[2-(4-BENZYL-4-HYDROXY-PIPERIDIN-1-YL)-ETHYL]-3-(2-METHYL-QUINOLIN-4-YL)-UREA AS CRYSTALLINE SULFATE SALT | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-20 | — | — | WO | claimed |
| EP-1453843-A2 | POWDER TRACE ELEMENT, METHOD AND DEVICE FOR MAKING SAME | Pancosma S.A. pour l'Industrie des Produits Biochimiques (CH) | 2004-09-08 | — | — | EP | claimed |
| WO-2003049850-A2 | POWDER TRACE ELEMENT, METHOD AND DEVICE FOR MAKING SAME | PANCOSMA SOCIETE ANONYME POUR L'INDUSTRIE DES PRODUITS BIOCHIMIQUES (CH) | 2003-06-19 | — | — | WO | claimed |
| EP-1289923-A2 | EPITHELIAL CELL CANCER DRUG | Lifelink Pharmaceuticals Inc. (US) | 2003-03-12 | — | — | EP | claimed |
| WO-2001093877-A2 | EPITHELIAL CELL CANCER DRUG | LIFELINK PHARMACEUTICALS, INC. (US) | 2001-12-13 | — | — | WO | claimed |
| US-6288045-B1 | ADMINISTERING 4,6 CYCLO, TRISILICO, TRIMAGNESIUM, TRIALUMINO, OXYO TRIHYDRATE ACETATE; SIDE EFFECT REDUCTION | LIFELINK PHARMACEUTICALS, INC. | 2001-09-11 | — | — | US | claimed |
| US-4332650-A | Thermoelectrochemical process using copper oxide for producing hydrogen and oxygen from water | GAS RESEARCH INSTITUTE (US) | 1982-06-01 | — | — | US | claimed |
| US-4192726-A | Thermoelectrochemical process using copper sulfate for producing hydrogen and oxygen from water | GAS RESEARCH INSTITUTE (US) | 1980-03-11 | — | — | US | claimed |
| EP-4683923-A1 | HYDROGEN SULFATE COMPLEXES, INCLUDING SALTS, CRYSTALLINE FORMS, AND HYDRATES AND SOLVATES OF ENT1 INHIBITORS | iTeos Belgium SA (BE) | 2026-01-28 | — | — | EP | disclosed |
| CN-120119335-A | Lithium-containing compound chalcogen and chalcogen two-dimensional crystal, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2025-06-10 | — | — | CN | disclosed |
| EP-0342544-A1 | Anti-aids Virus agent | TAITO CO., LTD. (JP) | 1989-11-23 | — | — | EP | disclosed |
| EP-0308983-A2 | NMR imaging with Mn(II) coordination compositions | SALUTAR, INC. (US) | 1989-03-29 | — | — | EP | disclosed |